Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.54 |
| ▸ | HMGCR | P04035 | 3/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 3/20 | 0.48 |
| ▸ | PPARD | Q03181 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979048 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL1050169 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL40510 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL2802414 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL20293445 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL2803510 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL2985078 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL12680242 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL257132 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL29377936 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136965-A | Isolated polypeptide of targeted MPP8 protein and application thereof | 苏州系统医学研究所 | 2025-06-13 | — | — | CN | claimed |
| CN-116444258-B | Foamed ceramic prepared from steel slag and red mud and process thereof | 江门市俞嘉科技有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-101863732-B | Synthesis method of end-group alkyne | SHANGHAI RUIYI MEDICAL TECHNOLOGY CO LTD | 2013-08-07 | — | — | CN | claimed |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4665332-A2 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4650348-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| EP-4634184-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | Crossfire Oncology Holding B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| US-20250288573-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-3893934-B1 | INSULIN CONJUGATES | SANOFI SA (FR) | 2025-09-10 | — | — | EP | disclosed |
| US-20250206798-A1 | INSULIN CONJUGATES | SANOFI SA (FR) | 2025-06-26 | — | — | US | disclosed |
| US-20060111359-A1 | enzyme inhibitor for treating sleep disorders | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-05-25 | — | — | US | disclosed |
| US-20060111269-A1 | Depot preparations | SYMRISE AG (DE) | 2006-05-25 | — | — | US | disclosed |
| CN-1703407-A | fatty acid amide hydrolase inhibitors | SCRIPPS RESEARCH INST (US) | 2005-11-30 | — | — | CN | disclosed |
| EP-1549624-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | The Scripps Research Institute (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004033652-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20030114352-A1 | Depot preparations | SYMRISE GMBH & CO. KG (DE) | 2003-06-19 | — | — | US | disclosed |
| US-20030083376-A1 | Depot preparations | SYMRISE GMBH & CO. KG (DE) | 2003-05-01 | — | — | US | disclosed |
| US-4871868-A | FROM AN ORGANIC HALIDE OR AN ARYL SULFONATE AND AN ALKALI METAL ACETYLIDE, 1,3-DIALKYL-2-IMIDAZOLIDINONE PROMOTER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-10-03 | — | — | US | disclosed |
| EP-0284237-A1 | Production of substituted acetylenic compounds | Takeda Chemical Industries, Ltd. (JP) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111359-A1 | enzyme inhibitor for treating sleep disorders | FAAH, FAAH2, HCRTR2 | HSD17B10 118/4885CYP1A2 46/4885CYP2D6 285/4885 |
| US-20030083376-A1 | Depot preparations | FABP4, ADH1C, LIPE | HSD17B10 45/4885CYP1A2 198/4885CYP2D6 666/4885 |
| US-20250288573-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | CRBN, CD4, CDR2 | HSD17B10 3514/4885CYP1A2 4199/4885CYP2D6 3818/4885 |
| US-20030114352-A1 | Depot preparations | FABP4, LIPE, GPR119 | HSD17B10 44/4885CYP1A2 155/4885CYP2D6 580/4885 |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | HSD17B10 1083/4885CYP1A2 1719/4885CYP2D6 2393/4885 |
| US-20250206798-A1 | INSULIN CONJUGATES | IAPP, INSR, IGF1R | HSD17B10 1314/4885CYP1A2 1696/4885CYP2D6 1147/4885 |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CDK2, CCNK, CCNC | HSD17B10 1607/4885CYP1A2 1915/4885CYP2D6 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.